Michele Bianchini

Identification of Predictive Biomarkers Based on Cytokine Profiles for Molecular Relapse After Treatment-Free Remission in Chronic Myeloid Leukemia Patients

Bianca Vasconcelos Cordoba, Carolina Pavlovsky, María Belén Sanchez, Elena Beatriz Moiraghi et autres

Tyrosine kinase inhibitors (TKIs) have transformed chronic myeloid leukemia (CML) into a manageable disease, and discontinuation has become a feasible goal for many patients. However, molecular relapse after TKI cessation remains a challenge. This study investigated factors influencing molecular relapse-free survival (MRFS) …

ar, uy (code pays fourni par la source)

The adverse prognostic impact of HMGCLL1 gene variants can be abrogated by frontline second-generation tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia

María Agustina Perusini, Katia Pagnano, Carolina Pavlovsky, Daniela Žáčková et autres

ca, br, ar, cz, kr (code pays fourni par la source)

Integrating cytokine profiles with clinical and molecular biomarkers to predict molecular relapse after TKI discontinuation in CML patients

Carolina Pavlovsky, Bianca Vasconcelos Cordoba, María‐José Sánchez, Elena Beatriz Moiraghi et autres

Abstract Background The introduction of tyrosine kinase inhibitors (TKIs) has improved the management of chronic myeloid leukemia (CML), making treatment-free remission (TFR) an attainable objective. Despite this, half of the patients lose their major molecular response (MMR) within the first six months …

ar (code pays fourni par la source)

The Influence of the COVID-19 Pandemic in NK Cell Subpopulations from CML Patients Enrolled in the Argentina Stop Trial

María Belén Sánchez, Bianca Vasconcelos Cordoba, Carolina Pavlovsky, Beatriz Moiraghi et autres

Treatment-free remission (TFR) is a key therapeutic goal for chronic myeloid leukemia (CML) patients in deep molecular response (DMR). While predicting patient outcome remains challenging, different NK cell populations seem crucial. We conducted an immunological sub-study from the Argentina Stop Trial (AST), …

ar (code pays fourni par la source)

Final Report: Somatic Mutations and HMGCLL1 Haplotype Are Not Associated with Molecular Relapse-Free Survival in Patients with Chronic Myeloid Leukemia Who Attempt Treatment-Free Remission

María Agustina Perusini, Kátia Bórgia Barbosa Pagnano, Carolina Pavlovsky, Beatriz Moiraghi et autres

Background Chronic myeloid leukemia (CML) is a clonal hematopoietic stem cell disorder resulting from the BCR::ABL1 rearrangement. Patients with CML have a comparable life expectancy to that of age-matched individuals in the general population when they achieve an optimal response with tyrosine …

ca, br, ar, it, cz (code pays fourni par la source)

Long-Term Follow-up of the AST Trial of Treatment-Free Remission in Chronic Myeloid Leukemia Patients

Ricardo Khalil Tannuri, Beatriz Moiraghi, Ana Inés Varela, Michele Bianchini et autres

Background: Treatment-free remission (TFR) is a new goal for chronic myeloid leukemia (CML) patients who achieved a long deep molecular response (DMR) with better quality of life, reduced adverse events and high economic impact. The primary objective of the AST trial was …

ar (code pays fourni par la source)

In-depth characterization of NK cell markers from CML patients who discontinued tyrosine kinase inhibitor therapy

María Belén Sánchez, Bianca Vasconcelos Cordoba, Carolina Pavlovsky, Beatriz Moiraghi et autres

Introduction: Treatment-free remission (TFR) in patients with chronic myeloid leukemia in chronic phase is considered a safe option if suitable molecular monitoring is available. However, the question arises as to which factors can contribute to the maintenance of TFR, and immunologic surveillance …

ar (code pays fourni par la source)

Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal

Carolina Pavlovsky, Bianca Vasconcelos Cordoba, María Belén Sánchez, Beatriz Moiraghi et autres

Abstract Treatment-free remission (TFR) in chronic myeloid leukemia (CML) is safe under adequate molecular monitoring, but questions remain regarding which factors may be considered predictive for TFR. Argentina Stop Trial (AST) is a multicenter TFR trial showing that 65% of patients sustain …

ar (code pays fourni par la source)

Data from Metallothionein 1G and Zinc Sensitize Human Colorectal Cancer Cells to Chemotherapy

Juan Martín Arriaga, Angela Greco, José Mordoh, Michele Bianchini

Abstract Metallothioneins (MT) are a family of low molecular weight proteins that are silenced during colorectal cancer progression, mainly through epigenetic mechanisms, and this loss is associated with poor survival. In this article, we show that overexpression of the MT1G isoform sensitizes …

Supplementary Figure Legends, Supplementary Table 1, and Supplementary Figures 1 through 8 from Metallothionein 1G and Zinc Sensitize Human Colorectal Cancer Cells to Chemotherapy

Juan Martín Arriaga, Angela Greco, José Mordoh, Michele Bianchini

PDF - 1320K, Contains Legends to Supplementary Figures; Supplementary Table 1: sequences for primers and siRNAs; Supplementary Figure 1: IC50 curves for chemoresistant cell lines; Supplementary Figure 2: Proliferation and dose-response curves for MT1G+ clones, as well as cell cycle analysis results; …

Supplementary Figure Legends, Supplementary Table 1, and Supplementary Figures 1 through 8 from Metallothionein 1G and Zinc Sensitize Human Colorectal Cancer Cells to Chemotherapy

Juan Martín Arriaga, Angela Greco, José Mordoh, Michele Bianchini

PDF - 1320K, Contains Legends to Supplementary Figures; Supplementary Table 1: sequences for primers and siRNAs; Supplementary Figure 1: IC50 curves for chemoresistant cell lines; Supplementary Figure 2: Proliferation and dose-response curves for MT1G+ clones, as well as cell cycle analysis results; …

Data from Metallothionein 1G and Zinc Sensitize Human Colorectal Cancer Cells to Chemotherapy

Juan Martín Arriaga, Angela Greco, José Mordoh, Michele Bianchini

Abstract Metallothioneins (MT) are a family of low molecular weight proteins that are silenced during colorectal cancer progression, mainly through epigenetic mechanisms, and this loss is associated with poor survival. In this article, we show that overexpression of the MT1G isoform sensitizes …